Association of Intravenous Alteplase, Early Reperfusion, and Clinical Outcome in Patients With Large Vessel Occlusion Stroke: Post Hoc Analysis of the Randomized DIRECT-MT Trial.

Abstract

BACKGROUND:

The added value of intravenous alteplase in reperfusing ischemic brain tissue in patients undergoing endovascular treatment and directly presented to an endovascular treatment-capable hospital is uncertain. We conducted this post hoc analysis of a randomized trial (DIRECT-MT [Direct Intraarterial Thrombectomy in Order to Revascularize Acute Ischemic Stroke Patients With Large Vessel Occlusion Efficiently in Chinese Tertiary Hospitals: A Multicenter Randomized Clinical Trial]) to explore the association of intravenous alteplase, early (preendovascular treatment) reperfusion, and clinical outcome and to determine factors which may modify alteplase treatment effect on early reperfusion.

METHODS:

In this post hoc analysis of the DIRECT-MT randomized trial comparing intravenous alteplase before endovascular treatment versus endovascular treatment only, 623 of 656 randomized patients, with adequate angiographic evaluation for early reperfusion assessment, were included. The association of intravenous alteplase and early reperfusion (defined as expanded Thrombolysis in Cerebral Infarction score ≥2a on angiogram) was assessed using unadjusted comparisons and multivariable logistic regression.

RESULTS:

Among 623 patients included (317 received intravenous alteplase and 306 did not), early reperfusion occurred in 91 (15%) patients and was associated with better functional outcome (modified Rankin Scale score, 0-2 of 49/91 [54%] versus 178/531 [34%]; adjusted odds ratio, 1.92 [95% CI, 1.15-3.21]; P<0.001). Intravenous alteplase was independently associated with early reperfusion (59/317 [19%] versus 32/306 [10%]; adjusted odds ratio, 2.06 [95% CI, 1.27-3.33]; P=0.003), and the alteplase effect was modified by time from randomization to groin puncture (dichotomized by median, ≤33 minutes; adjusted odds ratio, 1.06 [95% CI, 0.53-2.10] versus >33 minutes; adjusted odds ratio, 4.07 [95% CI, 1.86-8.86]; Pinteraction=0.012).

CONCLUSIONS:

For patients with large vessel occlusion directly presenting to an endovascular treatment-capable hospital, intravenous alteplase increases early reperfusion when endovascular treatment gets delayed more than approximately half an hour. Thus, intravenous alteplase should be considered if endovascular treatment delays are anticipated by the treating medical team.

REGISTRATION:

URL: https://www.

CLINICALTRIALS:

gov; Unique identifier: NCT03469206.

• Authors: Yu Zhou, Lei Zhang, Johanna Ospel, Mayank Goyal, Rosalie McDonough, Pengfei Xing, Zifu Li, Xiaoxi Zhang, Yongxin Zhang, Yongwei Zhang, Bo Hong, Yi Xu, Qinghai Huang, Qiang Li, Ying Yu, Qiao Zuo, Xiaofei Ye, Pengfei Yang, Jianmin Liu, DIRECT-MT Investigators
• Journal: Stroke (Stroke) Vol. 53 Issue 6 Pg. 1828-1836 (06 2022) ISSN: 1524-4628 [Electronic] United States
• PMID: 35240861 (Publication Type: Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Fibrinolytic Agents
• Tissue Plasminogen Activator

Topics

• Arterial Occlusive Diseases (drug therapy)
• Brain Ischemia (diagnostic imaging, drug therapy, surgery)
• Endovascular Procedures
• Fibrinolytic Agents
• Humans
• Ischemic Stroke
• Reperfusion
• Stroke (diagnostic imaging, drug therapy, surgery)
• Thrombectomy
• Tissue Plasminogen Activator (therapeutic use)
• Treatment Outcome